🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
AD17002 enhances nasal mucosal innate immunity and has met safety and effic...
Status
Terminated
Location
RSPI Sulianti Saroso
Start Date
2022-12-01
Trial ID
NCT05541510
Treatments Being Tested
This study is performed to evaluate safety and to explore the efficacy of a...
Status
Terminated
Location
Seoul National University Bundang Hospital
Start Date
2017-03-07
Trial ID
NCT03089697
Treatments Being Tested
AD17002 has demonstrated superior safety and efficacy as a nasal adjuvant f...
Status
Completed
Location
Advagene Biopharma
Start Date
2022-03-21
Trial ID
NCT05069610
Treatments Being Tested
Multi-center, dose-regimen, double-blind study evaluating the safety and ef...
Status
Recruiting
Location
California Dermatology & Clinical Research Institute
Start Date
2022-07-25
Trial ID
NCT05501327
Treatments Being Tested
This phase 2 study will evaluate the safety, immunogenicity and optimal tim...
Status
Completed
Location
Desmond Tutu HIV Centre Cape Town
Start Date
2005-10
Trial ID
NCT00888446
Treatments Being Tested
The purpose of this study is to assess the safety and tolerability of intra...
Status
Completed
Location
Multiple Locations
Start Date
2015-09
Trial ID
NCT02561871
Treatments Being Tested
A Phase 1 study to assess the bioavailability and pharmacokinetics of a 600...
Status
Completed
Location
Quotient Clinical
Start Date
2015-06
Trial ID
NCT02557789
Treatments Being Tested
This two-part trial will assess the safety, tolerability, pharmacokinetics,...
Status
Completed
Location
Keck Medicine of USC
Start Date
2019-07-16
Trial ID
NCT03989440
Study CSL324\_1003 is a single center, randomized, double-blind, placebo-co...
Status
Completed
Location
Scientia Clinical Research Ltd
Start Date
2020-10-08
Trial ID
NCT04570267
During the first 26 weeks of the trial, participants were randomly assigned...
Status
Completed
Location
Ascendis Pharma Investigational Site
Start Date
2021-02-16
Trial ID
NCT04701203
Treatments Being Tested